Biomatters' Geneious Biologics SAAS

Biomatters has released a new version of Geneious Biologics, an enterprise software-as-a-service solution for commercial antibody screening and discovery. The new release features a capability that will allow developers of biological drugs to analyze millions of raw antibody sequences in minutes, accelerating the identification of therapeutic antibody candidates. The software enables users to preview, annotate, and compare NGS sequnces with no manual intervention, the company noted.